查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1355208

化療市場 - 2018-2028F 全球產業規模、佔有率、趨勢、機會和預測，按類型、適應症、劑型、給藥途徑、最終用戶、地區和競爭細分

Chemotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F Segmented By Type, By Indication, By Dosage Form, By Route of Administration, By End User, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年全球化療市場價值為 82.6 億美元，預計在預測期內將強勁成長，到 2028 年複合年成長率為 8.51%。世界衛生組織 (WHO) 指出，癌症是第二大原因全球死亡率增加，預計2018 年有960 萬人死亡。鑑於癌症發生率不斷上升，對化療藥物的需求將會增加。化療是一種癌症治療方法，利用強效化學物質瞄準並消除體內快速分裂的細胞。它已被證明可以有效減少癌細胞數量、阻止癌症進展和縮小腫瘤。

化療通常是單獨或合併使用，是治療多種癌症的一般治療方式。它作為主要或唯一的治療方法，消除隱藏的癌細胞並為患者準備其他干預措施，例如放射或手術。此外，它還可以透過選擇性地靶向癌細胞來減輕與癌症相關的體徵和症狀。

主要市場促進因素

市場概況
預測期 2024-2028
2022 年市場規模 82.6億美元
2028 年市場規模 133.9億美元
2023-2028 年複合年成長率 8.51%
成長最快的細分市場 烷基化劑
最大的市場 北美洲

癌症發生率上升

癌症盛行率的增加預計將推動化療藥物市場的成長。根據世界衛生組織 (WHO) 的數據，癌症是全球死亡的主要原因，2020 年約有 1,000 萬人因癌症死亡，即近六分之一的死亡。每年，大約有 40 萬名兒童接受癌症診斷。子宮頸癌是全球 23 個國家最常見的癌症。化療通常與其他癌症治療結合使用，仍然是癌症治療的主要方法。新輔助化療是指在手術前進行化療和放射治療以縮小腫瘤大小，而輔助化療是在手術或放射治療後進行以進一步縮小腫瘤。

增加醫療基礎建設投資

影響化療藥物市場成長率的另一個重要因素是醫療保健支出的增加，這有助於其基礎設施的改善。此外，各政府組織致力於透過增加資金來加強醫療基礎設施，進而影響市場動態。增加的投資可以建立和擴大專門的癌症治療中心，配備最先進的化療管理、監測和支持護理設施。醫療保健基礎設施投資確保患者能夠接觸到腫瘤學家、血液學家、病理學家、放射科醫生和其他在規劃和提供化療治療中發揮關鍵作用的專家。設備齊全的醫療設施可以透過先進的影像技術、活體組織切片和分子檢測提供準確、及時的癌症診斷，指導選擇合適的化療方案。充足的基礎設施支持臨床試驗的進行，使患者能夠獲得創新的化療治療，並有助於開發新的治療方案。此外，老年人口的擴大和對先進抗癌藥物不斷成長的需求將推動化療藥物市場的擴大。此外，人們對化療的認知不斷增強，加上接受化療和放療的患者數量不斷增加，預計將促進市場的成長。

老年人口增加

全球老年人口的增加，加上慢性病盛行率的上升，正在推動預測期內市場的成長。值得注意的是，2019年，60歲及以上人口在人口中的數量和比例達到10億，預計到2030年，這一數字將增至14億，到2050年將增至21億。此外，報銷政策的完善預計經濟將有助於市場的擴張。此外，全球患者人數的成長和醫療基礎設施的進步將推動市場。

此外，全球癌症發生率不斷上升是推動市場成長的重要因素。根據世界衛生組織統計，2020年約有1,000萬人死於癌症。值得注意的是，肺癌死亡人數最多，達180萬人，其次是結腸癌和直腸癌（91.6萬人死亡）、肝癌（83萬人類死亡） ）、胃癌（769,000 人死亡）和乳癌（685,000 人死亡）。此外，據觀察，低收入和中低收入國家約 30% 的癌症病例是由人類乳突病毒 (HPV) 和肝炎等致癌物質引起的。此外，增加對研發活動的投資以開發更有效的醫療解決方案，再加上新產品的推出，預計將在整個預測期內推動全球化療市場的成長。

增加研發活動

研發工作的重點是確定癌細胞中可用於治療的特定分子標靶。標靶治療旨在攻擊癌細胞，同時最大限度地減少對健康細胞的損害，減少副作用並提高治療效果。基因組學和分子分析的進步使得能夠開發針對個別患者的基因組成和癌症特徵的個人化化療方案。這種方法提高了治療精確度並增加了積極反應的可能性。研發導致了具有不同作用機制的新化療藥物的發現和開發。這些藥物可能具有提高療效、降低毒性和對抗抗藥性的新方法。研究人員正在探索化療藥物與其他治療方法的組合，例如免疫療法、標靶療法和放射療法。這些組合可以增強整體治療效果並克服抗藥性。創新的藥物傳遞系統，包括奈米顆粒、脂質體和植入物，可改善化療藥物的藥物動力學和生物利用度，提高其有效性並減少副作用。研發旨在了解抗藥性機制並制定克服抗藥性的策略，從而延長化療的有效性。研究人員致力於開發副作用越來越少的化療藥物，從而改善患者在治療期間的生活品質。

主要市場挑戰

治療費用高

化療藥物的高成本對市場的成長構成了重大障礙。高額化療費用可能會給患者帶來經濟障礙，導致治療延遲或延遲、不遵守規定的治療方案以及治療效果降低。經濟資源有限的患者可能在接受化療方面面臨差異，加劇現有的醫療保健不平等。高成本會影響患者的治療決策，可能導致基於財務考量而不是醫療必要性的次優選擇。化療的經濟壓力可能會導致治療機會減少，特別是對於沒有保險或保險不足的患者。此外，發展中經濟體缺乏熟練專業人員和醫療基礎設施不足，為化療藥物市場帶來了挑戰。此外，這些藥物的副作用，包括心臟問題、紅血球計數減少、疲勞、體重減輕、脫髮、腹瀉、肺、腎和肝功能下降、骨密度下降以及公眾認知有限，限制並進一步阻礙2018-2028 年預測期內市場的成長。

治療對健康的不良影響

化療通常會帶來一系列副作用，包括噁心、嘔吐、疲勞、脫髮、疼痛和認知改變。這些副作用會顯著降低患者的生活品質並導致身體和情緒困擾。出現嚴重副作用的前景可能會導致一些患者避免或延遲化療治療。不依從可能會影響治療效果並阻礙正面的結果。一些化療藥物可能會產生潛在的長期健康後果，例如器官損傷或繼發性癌症，這可能會影響患者接受治療的意願。

主要市場趨勢

創新技術開發

化療在延長癌症患者的壽命方面發揮了關鍵作用，比他們的預期生存期多了幾年。化療領域的最新突破涉及使用專門設計的含有抗癌藥物的奈米顆粒，它可以選擇性地針對受影響的區域，同時保護健康細胞。這種創新方法在根除惡性細胞同時保護周圍健康組織方面表現出顯著的功效。透過利用光子雷射器，醫療專業人員能夠精確監測這些載藥奈米顆粒在患者體內的釋放、持續時間和分佈。令人興奮的是，加州大學洛杉磯分校目前正在進行一項臨床試驗，以評估這種方法的有效性，該方法在治療早期癌症患者方面顯示出有希望的結果。隨著即將進入化療市場，這項突破性技術在改變癌症治療方面具有巨大潛力。

研發活動數量的增加

化療藥物市場的成長是由研發活動的增加所推動的，為市場擴張提供了有利的機會。研究計劃的重點是確定化療藥物的新化合物、分子和作用機制。新藥的發現擴大了可用治療選擇的範圍，並解決了未滿足的醫療需求。研發旨在開發標靶化療藥物，專門攻擊癌細胞，同時最大限度地減少對健康細胞的傷害。這些療法可提高療效並減少副作用。研究探討了化療藥物與免疫療法或標靶治療等其他治療方式結合的協同效應，從而產生更全面、更有效的癌症治療方案。研發工作確定了可以預測患者對特定化療藥物反應的生物標記物，從而實現個人化治療選擇並改善治療結果。持續的研究導致最佳化藥物配方的開發，包括緩釋配方、奈米顆粒和脂質體，從而增強藥物傳輸、生物利用度和患者依從性。此外，預測期內新興市場數量的增加和新產品的推出將進一步促進化療藥物市場成長的積極前景。

細分市場洞察

類型洞察

化療市場依藥物類別細分，包括烷化劑、抗代謝物、抗腫瘤抗生素、荷爾蒙、單株抗體等。烷化劑領域目前在市場上佔據主導地位。已知烷基化物質會導致 DNA 鏈斷裂、奇數鹼基配對或 DNA 鏈交聯，最終阻礙細胞分裂。此外，烷基化化學物質通常被認為是細胞週期非特異性的，因為它們能夠在細胞週期的不同點消除細胞。隨著全球癌症發生率持續上升，抗代謝藥物市場預計將大幅擴張。此外，抗代謝藥物產業的成長也可歸因於管道研究的增加和醫療保健成本的不斷上升。

管理途徑見解

口服類別是市場上最大的貢獻者，預計在整個預測期內將出現顯著擴張。口腔癌治療藥物有丸劑、膠囊或液體形式。在家中，減少頻繁前往醫療機構進行靜脈輸液的需要。這對於居住在遠離治療中心的患者尤其有益。在家服用化療藥物的能力可以為患者帶來更好的生活品質，因為他們對治療計劃有更大的靈活性和控制力。與靜脈注射治療相比，口服化療可能有助於減少住院時間和相關費用，從而節省潛在的醫療費用。口服化療可最大限度地減少對患者日常生活和活動的干擾，使他們能夠繼續工作、與家人共度時光以及從事其他正常活動。然而，靜脈注射途徑的成長速度最快。由於以靜脈注射給藥，化療藥物比口服和局部治療藥物起效更快，因為它們能迅速吸收到血液中。

區域洞察

在多家化療藥物製造商和醫療支出增加的推動下，北美化療市場有望主導該產業。醫療設施的便利性以及尖端技術在癌症研究和治療中的應用進一步促進了其成長。

歐洲化療市場佔據第二大市場佔有率，這得益於新癌症療法的法規核准便利性、癌症發病率上升以及市場上主要公司的大量研發投資。值得注意的是，德國化療市場擁有最大的市場佔有率，而英國化療市場在歐洲地區的成長率最高。

預計 2023 年至 2028 年，亞太化療市場將快速擴張。這可歸因於該地區政府的意識措施和不斷上升的醫療成本。訓練有素的醫療保健提供者的可用性和對化療藥物的需求不斷增加，加上學名藥的可及性不斷擴大，預計將減緩市場的成長率。此外，中國化療市場佔有最大的市場佔有率，印度化療市場在亞太地區成長最高。

主要市場參與者

  • F.霍夫曼-拉羅氏有限公司
  • 邁蘭公司
  • 梯瓦製藥工業股份有限公司
  • 賽諾菲
  • 輝瑞公司
  • 葛蘭素史克公司
  • 諾華公司
  • 拜耳公司
  • 禮來公司
  • 默克公司

報告範圍：

化療市場，依類型：

  • 烷基化劑
  • 抗代謝藥
  • 抗腫瘤抗生素
  • 荷爾蒙
  • 單株抗體
  • 其他

化療市場，依適應症分類：

  • 腫瘤學/癌症
  • 骨髓疾病
  • 免疫系統疾病
  • 其他

化療市場，按劑型：

  • 膠囊
  • 平板電腦
  • 注射
  • 其他

化療市場，依給藥途徑分類：

  • 口服
  • 注射用
  • 其他

化療市場，依最終用戶分類：

  • 醫院
  • 專科診所
  • 其他

化療市場（按地區）：

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 法國
    • 英國
    • 義大利
    • 德國
    • 西班牙
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特
    • 土耳其
    • 埃及

競爭格局

公司概況：全球化療市場主要公司的詳細分析。

可用的客製化：

全球化療市場報告以及給定的市場資料，技術科學研究根據公司的具體需求提供客製化服務。該報告可以使用以下自訂選項：

公司資訊

  • 其他市場參與者（最多五個）的詳細分析和概況分析。

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球化療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型（烷化劑、抗代謝物、抗腫瘤抗生素、荷爾蒙、單株抗體、其他）
    • 按適應症（腫瘤/癌症、骨髓疾病、免疫系統疾病、其他）
    • 按劑型（膠囊、錠劑、注射劑、其他）
    • 依給藥途徑（口服、腸胃外、其他）
    • 按最終使用者（醫院、專科診所、其他）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖

第 6 章：北美化療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 依劑型分類
    • 依給藥途徑
    • 由最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第 7 章：歐洲化療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 依劑型分類
    • 依給藥途徑
    • 由最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太化療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 依劑型分類
    • 依給藥途徑
    • 由最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲化療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 依劑型分類
    • 依給藥途徑
    • 由最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲化療市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按類型
    • 按指示
    • 依劑型分類
    • 依給藥途徑
    • 由最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非化療
    • 沙烏地阿拉伯化療
    • 阿拉伯聯合大公國化療

第 11 章：市場動態

第 12 章：市場趨勢與發展

第 13 章：全球化療市場：SWOT 分析

第14章：競爭格局

  • 商業概覽
  • 應用程式產品
  • 最近的發展
  • 主要人員
  • SWOT分析
    • F. Hoffmann-La Roche Ltd.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Bayer AG
    • Eli Lilly and Company
    • Merck & Co., Inc.

第 15 章：策略建議

第 16 章：關於我們與免責聲明

簡介目錄
Product Code: 4735

The global Chemotherapy Market was valued at USD 8.26 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 8.51% through 2028. Cancer, as stated by the World Health Organization (WHO), is the second leading cause of mortality worldwide, resulting in an estimated 9.6 million deaths in 2018. Given the rising cancer rates, there will be an increased demand for chemotherapy medications. Chemotherapy is a cancer treatment approach that utilizes potent chemicals to target and eliminate rapidly dividing cells within the body. It has proven efficacy in reducing cancer cell count, impeding cancer progression, and shrinking tumors.

Chemotherapy, often administered alone or in combination, is a versatile treatment modality for a wide range of cancers. It serves as a primary or sole treatment, eliminating hidden cancer cells and preparing patients for other interventions such as radiation or surgery. Additionally, it can be employed to alleviate cancer-related signs and symptoms by selectively targeting cancer cells.

Key Market Drivers

Market Overview
Forecast Period2024-2028
Market Size 2022USD 8.26 Billion
Market Size 2028USD 13.39 Billion
CAGR 2023-20288.51%
Fastest Growing SegmentAlkylating Agents
Largest MarketNorth America

Rising Incidences of Cancers

The increasing prevalence of cancer is projected to drive the growth rate of the chemotherapy drug market. According to the World Health Organization (WHO), cancer is the leading cause of mortality worldwide, accounting for approximately 10 million deaths in 2020, or nearly one in every six deaths. Each year, around 400,000 children receive a cancer diagnosis. Cervical cancer ranks as the most common cancer in 23 countries across the globe. Chemotherapy, often used in conjunction with other cancer treatments, remains the predominant approach to cancer treatment. Neo-adjuvant chemotherapy refers to chemotherapy administered prior to surgery and radiation therapy to reduce tumor size, while adjuvant chemotherapy is administered after surgery or radiation therapy to further shrink the tumor.

Increasing Investment in Healthcare Infrastructure

Another significant factor impacting the growth rate of the chemotherapy drug market is the increasing healthcare expenditure, which contributes to the improvement of its infrastructure. Moreover, various government organizations are committed to enhancing healthcare infrastructure through increased funding, thereby influencing market dynamics. Increased investment allows for the establishment and expansion of specialized cancer treatment centers equipped with state-of-the-art facilities for chemotherapy administration, monitoring, and supportive care. Healthcare infrastructure investment ensures that patients have access to oncologists, hematologists, pathologists, radiologists, and other specialists who play critical roles in planning and delivering chemotherapy treatments. Well-equipped healthcare facilities can provide accurate and timely cancer diagnoses through advanced imaging technologies, biopsies, and molecular testing, guiding the selection of appropriate chemotherapy regimens. Adequate infrastructure supports the conduct of clinical trials, allowing patients to access innovative chemotherapy treatments and contributing to the development of new therapeutic options. Furthermore, the expanding geriatric population and the growing demand for advanced cancer drugs will drive the expansion of the chemotherapy drug market. Additionally, the growing awareness of chemotherapy, coupled with the rising number of patients undergoing chemotherapy and radiotherapy treatments, is expected to augment the market's growth.

Increasing Geriatric Population

The increase in the geriatric population worldwide, coupled with a rising prevalence of chronic diseases, is driving the market's growth during the forecast period. It is worth noting that the number and proportion of individuals aged 60 years and older in the population reached 1 billion in 2019, and this figure is projected to rise to 1.4 billion by 2030 and 2.1 billion by 2050. Moreover, improved reimbursement policies in advanced economies are expected to contribute to the market's expansion. Additionally, the market will be propelled by the growing patient population globally and advancements in healthcare infrastructure.

Furthermore, the escalating incidence of cancer worldwide is a significant factor driving market growth. According to the World Health Organization, approximately 10 million people succumbed to cancer in 2020. Notably, lung cancer accounted for the highest number of deaths, with 1.80 million fatalities, followed by colon and rectum cancer (916,000 deaths), liver cancer (830,000 deaths), stomach cancer (769,000 deaths), and breast cancer (685,000 deaths). Additionally, it has been observed that about 30% of cancer cases in low and lower-middle-income countries are caused by cancer-causing agents such as the human papillomavirus (HPV) and hepatitis. Moreover, increased investments in research and development activities to develop more effective medical solutions, coupled with the launch of new products, are expected to drive the growth of the global chemotherapy market throughout the forecast period.

Increasing Research & Development Activities

R&D efforts are focused on identifying specific molecular targets in cancer cells that can be exploited for treatment. Targeted therapies aim to attack cancer cells while minimizing damage to healthy cells, reducing side effects, and improving treatment efficacy. Advancements in genomics and molecular profiling enable the development of personalized chemotherapy regimens tailored to an individual patient's genetic makeup and cancer characteristics. This approach enhances treatment precision and increases the likelihood of positive responses. R&D leads to the discovery and development of new chemotherapy drugs with different mechanisms of action. These drugs may have improved efficacy, reduced toxicity, and novel ways of combating drug resistance. Researchers are exploring combinations of chemotherapy agents with other treatments, such as immunotherapy, targeted therapy, and radiation therapy. These combinations can enhance the overall therapeutic effect and overcome resistance. Innovative drug delivery systems, including nanoparticles, liposomes, and implants, improve the pharmacokinetics and bioavailability of chemotherapy drugs, enhancing their effectiveness and reducing side effects. R&D aims to understand the mechanisms of drug resistance and develop strategies to overcome it, allowing for the prolonged effectiveness of chemotherapy treatments. Researchers work on developing chemotherapy agents that have fewer and less severe side effects, improving patients' quality of life during treatment.

Key Market Challenges

High Cost of Treatment

The high cost associated with chemotherapy drugs poses a significant obstacle to the growth of the market. High chemotherapy costs can create financial barriers for patients, leading to delayed or deferred treatment, non-adherence to prescribed regimens, and reduced treatment effectiveness. Patients with limited financial resources may face disparities in accessing chemotherapy treatments, exacerbating existing healthcare inequalities. High costs can influence patients' treatment decisions, potentially leading to suboptimal choices based on financial considerations rather than medical necessity. The financial strain of chemotherapy can lead to reduced treatment access, particularly for uninsured or underinsured patients. Moreover, the shortage of skilled professionals and inadequate healthcare infrastructure in developing economies present challenges to the chemotherapy drug market. Additionally, the side effects of these drugs, including heart problems, decreased red blood cell count, fatigue, weight loss, hair loss, diarrhea, reduced lung, kidney, and liver function, decreased bone density, and limited awareness among the public, act as restraints and further hinder the market's growth during the forecast period of 2018-2028.

Adverse Health Effects by Treatment

Chemotherapy is often associated with a range of side effects, including nausea, vomiting, fatigue, hair loss, pain, and cognitive changes. These side effects can significantly diminish patients' quality of life and lead to physical and emotional distress. The prospect of experiencing severe side effects may lead some patients to avoid or delay chemotherapy treatment. Non-adherence can compromise treatment efficacy and hinder positive outcomes. Some chemotherapy drugs may have potential long-term health consequences, such as organ damage or secondary cancers, which can impact patients' willingness to undergo treatment.

Key Market Trends

Development of Innovative Technology

Chemotherapy has played a pivotal role in extending the lifespan of cancer patients, surpassing their expected survival by several years. The latest breakthrough in the field of chemotherapy involves the administration of specially designed nanoparticles containing cancer-fighting medications, which selectively target affected areas while sparing healthy cells. This innovative approach has demonstrated remarkable efficacy in eradicating malignant cells while preserving surrounding healthy tissue. By utilizing photon lasers, medical professionals are able to precisely monitor the release, duration, and distribution of these medication-loaded nanoparticles within the patient's body. Excitingly, the University of California, Los Angeles, is currently conducting a clinical trial to evaluate the effectiveness of this approach, which has shown promising outcomes in the treatment of early-stage cancer patients. With its imminent entry into the chemotherapeutic market, this groundbreaking technique holds great potential for transforming cancer treatment.

Increase in the Number of Research and Development Activities

The growth of the chemotherapy drug market is driven by a rise in research and development activities, presenting advantageous opportunities for market expansion. Research initiatives focus on identifying new compounds, molecules, and mechanisms of action for chemotherapy drugs. The discovery of novel drugs expands the range of available treatment options and addresses unmet medical needs. R&D aims to develop targeted chemotherapy drugs that specifically attack cancer cells while minimizing harm to healthy cells. These therapies offer enhanced efficacy and reduced side effects. Research explores the synergistic effects of combining chemotherapy drugs with other treatment modalities, such as immunotherapy or targeted therapy, leading to more comprehensive and effective cancer treatment regimens. R&D efforts identify biomarkers that can predict patient responses to specific chemotherapy drugs, enabling personalized treatment selection and improving treatment outcomes. Ongoing research leads to the development of optimized drug formulations, including extended-release formulations, nanoparticles, and liposomes, enhancing drug delivery, bioavailability, and patient compliance. Additionally, the increasing number of emerging markets and new product launches during the forecast period will further contribute to the positive prospects for the growth of the chemotherapy drug market.

Segmental Insights

Type Insights

The chemotherapy market is segmented based on drug class, including Alkylating Agents, Anti-metabolites, Anti-Tumor Antibiotics, Hormones, Monoclonal Antibodies, and Others. The alkylating agent segment currently holds the dominant position in the market. Alkylating substances are known to cause DNA strand breakage, odd base pairing, or cross-linking of DNA strands, which ultimately obstruct cell division. Moreover, alkylating chemicals are generally regarded as cell cycle phase nonspecific, as they have the ability to eliminate cells at various points in the cell cycle. As cancer rates continue to rise globally, the market for anti-metabolite drugs is projected to witness significant expansion. Additionally, the growth of the anti-metabolite medication sector can also be attributed to increased pipeline research and the escalating healthcare costs.

Route of Administration Insights

The oral category, being the largest contributor in the market, is expected to demonstrate significant expansion throughout the projected period. An oral cancer treatment medication is available in the form of pills, capsules, or liquids. home, reducing the need for frequent visits to healthcare facilities for IV infusions. This can be particularly beneficial for patients who live far from treatment centers. The ability to take chemotherapy drugs at home can lead to a better quality of life for patients, as they have more flexibility and control over their treatment schedule. Oral chemotherapy may help reduce the need for hospital stays and associated costs compared to intravenous treatments, resulting in potential healthcare cost savings. Oral chemotherapy minimizes the disruption of patients' daily routines and activities, allowing them to continue working, spending time with family, and engaging in other normal activities. However, the intravenous route has exhibited the most rapid growth rate. Due to their intravenous administration, chemotherapy drugs act more swiftly compared to oral and topical treatments, as they are rapidly absorbed into the bloodstream.

Regional Insights

The North American chemotherapy market is poised to dominate the industry, driven by multiple manufacturers of chemotherapy drugs and increased healthcare spending. Accessibility to medical facilities and the application of cutting-edge technology in cancer research and treatment further contribute to its growth.

Europe's chemotherapy market holds the second-largest market share, fueled by the ease of regulatory approval for novel cancer therapies, rising cancer incidence, and significant R&D investments by major companies in the market. Notably, the German chemotherapy market boasts the largest market share, while the UK chemotherapy market exhibits the highest growth rate in the European region.

The Asia-Pacific Chemotherapy Market is projected to experience rapid expansion from 2023 to 2028. This can be attributed to government awareness initiatives and escalating healthcare costs in the region. The availability of trained healthcare providers and the increasing demand for chemotherapy drugs, coupled with the expanding accessibility of generic medications, are expected to moderate the market's growth rate. Additionally, China's chemotherapy market commands the largest market share, and the Indian chemotherapy market demonstrates the highest growth rate in the Asia-Pacific region.

Key Market Players

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc.

Report Scope:

In this report, the Global Chemotherapy Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Chemotherapy Market, By Type:

  • Alkylating Agents
  • Anti-metabolites
  • Anti-Tumor Antibiotics
  • Hormones
  • Monoclonal Antibodies
  • Others

Chemotherapy Market, By Indication:

  • Oncology/Cancer
  • Bone Marrow Diseases
  • Immune System Disorders
  • Others

Chemotherapy Market, By Dosage Form:

  • Capsule
  • Tablets
  • Injections
  • Others

Chemotherapy Market, By Route of Administration:

  • Oral
  • Parenteral
  • Others

Chemotherapy Market, By End User:

  • Hospitals
  • Specialty Clinics
  • Others

Chemotherapy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Chemotherapy Market.

Available Customizations:

Global Chemotherapy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Voice of Customer

5. Global Chemotherapy Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Alkylating Agents, Anti-metabolites, Anti-Tumor Antibiotics, Hormones, Monoclonal Antibodies, Others)
    • 5.2.2. By Indication (Oncology/Cancer, Bone Marrow Diseases, Immune System Disorders, Others)
    • 5.2.3. By Dosage Form (Capsule, Tablets, Injections, Others)
    • 5.2.4. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.5. By End User (Hospitals, Specialty Clinics, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2022)
  • 5.3. Market Map

6. North America Chemotherapy Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Indication
    • 6.2.3. By Dosage Form
    • 6.2.4. By Route of Administration
    • 6.2.5. By End Users
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Chemotherapy Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Dosage Form
        • 6.3.1.2.4. By Route of Administration
        • 6.3.1.2.5. By End Users
    • 6.3.2. Canada Chemotherapy Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Dosage Form
        • 6.3.2.2.4. By Route of Administration
        • 6.3.2.2.5. By End Users
    • 6.3.3. Mexico Chemotherapy Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Dosage Form
        • 6.3.3.2.4. By Route of Administration
        • 6.3.3.2.5. By End Users

7. Europe Chemotherapy Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Indication
    • 7.2.3. By Dosage Form
    • 7.2.4. By Route of Administration
    • 7.2.5. By End Users
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Chemotherapy Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Dosage Form
        • 7.3.1.2.4. By Route of Administration
        • 7.3.1.2.5. By End Users
    • 7.3.2. United Kingdom Chemotherapy Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Dosage Form
        • 7.3.2.2.4. By Route of Administration
        • 7.3.2.2.5. By End Users
    • 7.3.3. Italy Chemotherapy Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Dosage Form
        • 7.3.3.2.4. By Route of Administration
        • 7.3.3.2.5. By End Users
    • 7.3.4. France Chemotherapy Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Dosage Form
        • 7.3.4.2.4. By Route of Administration
        • 7.3.4.2.5. By End Users
    • 7.3.5. Spain Chemotherapy Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Dosage Form
        • 7.3.5.2.4. By Route of Administration
        • 7.3.5.2.5. By End Users

8. Asia-Pacific Chemotherapy Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Indication
    • 8.2.3. By Dosage Form
    • 8.2.4. By Route of Administration
    • 8.2.5. By End Users
    • 8.2.6. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Chemotherapy Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Dosage Form
        • 8.3.1.2.4. By Route of Administration
        • 8.3.1.2.5. By End Users
    • 8.3.2. India Chemotherapy Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Dosage Form
        • 8.3.2.2.4. By Route of Administration
        • 8.3.2.2.5. By End Users
    • 8.3.3. Japan Chemotherapy Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Dosage Form
        • 8.3.3.2.4. By Route of Administration
        • 8.3.3.2.5. By End Users
    • 8.3.4. South Korea Chemotherapy Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Dosage Form
        • 8.3.4.2.4. By Route of Administration
        • 8.3.4.2.5. By End Users
    • 8.3.5. Australia Chemotherapy Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Dosage Form
        • 8.3.5.2.4. By Route of Administration
        • 8.3.5.2.5. By End Users

9. South America Chemotherapy Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Indication
    • 9.2.3. By Dosage Form
    • 9.2.4. By Route of Administration
    • 9.2.5. By End Users
    • 9.2.6. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Chemotherapy Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Dosage Form
        • 9.3.1.2.4. By Route of Administration
        • 9.3.1.2.5. By End Users
    • 9.3.2. Argentina Chemotherapy Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Dosage Form
        • 9.3.2.2.4. By Route of Administration
        • 9.3.2.2.5. By End Users
    • 9.3.3. Colombia Chemotherapy Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Dosage Form
        • 9.3.3.2.4. By Route of Administration
        • 9.3.3.2.5. By End Users

10. Middle East and Africa Chemotherapy Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Indication
    • 10.2.3. By Dosage Form
    • 10.2.4. By Route of Administration
    • 10.2.5. By End Users
    • 10.2.6. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Chemotherapy Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Dosage Form
        • 10.3.1.2.4. By Route of Administration
        • 10.3.1.2.5. By End Users
    • 10.3.2. Saudi Arabia Chemotherapy Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Dosage Form
        • 10.3.2.2.4. By Route of Administration
        • 10.3.2.2.5. By End Users
    • 10.3.3. UAE Chemotherapy Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Dosage Form
        • 10.3.3.2.4. By Route of Administration
        • 10.3.3.2.5. By End Users

11. Market Dynamics

12. Market Trends & Developments

13. Global Chemotherapy Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Application Offerings
  • 14.3. Recent Developments
  • 14.4. Key Personnel
  • 14.5. SWOT Analysis
    • 14.5.1. F. Hoffmann-La Roche Ltd.
    • 14.5.2. Mylan N.V.
    • 14.5.3. Teva Pharmaceutical Industries Ltd.
    • 14.5.4. Sanofi
    • 14.5.5. Pfizer Inc.
    • 14.5.6. GlaxoSmithKline plc
    • 14.5.7. Novartis AG
    • 14.5.8. Bayer AG
    • 14.5.9. Eli Lilly and Company
    • 14.5.10. Merck & Co., Inc.

15. Strategic Recommendations

16. About Us & Disclaimer